<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520841</url>
  </required_header>
  <id_info>
    <org_study_id>2020-00321</org_study_id>
    <nct_id>NCT04520841</nct_id>
  </id_info>
  <brief_title>Clinical Trial Comparing Negative Pressure Wound Therapy and Standard Dry Dressings</brief_title>
  <acronym>BERLYTZ</acronym>
  <official_title>Monocentric Randomized Clinical Trial Comparing Negative Pressure Wound Therapy (PREVENA™) and Standard Dry Dressings on Oozing of Closed Incision After Revision Total Hip and Knee Arthroplasty Surgery or Lower Extremity Amputation Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Lausanne Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Negative pressure dressings are currently widely used in wound management. Their use is&#xD;
      gradually being extended to surgical scars. However, studies demonstrating a clear benefit&#xD;
      are rare, particularly in terms of postoperative discharge, the need for surgical revision&#xD;
      due to prolonged oozing and cost.&#xD;
&#xD;
      The aim of this study is to evaluate the benefit of such a device in post-operative revision&#xD;
      prosthesis surgery (hip and knee), as well as lower limb amputations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Discharge after 7 days</measure>
    <time_frame>Day 7- Day 8</time_frame>
    <description>Presence of discharge at 7 days postoperatively (Day 7) Condition of the dry dressing applied on Day 7 and evaluated at least 24 hours after application (Day 8)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Day 0 - Day 14</time_frame>
    <description>Occurrence of post-operative complications from Day 0 to hospital discharge (or max Day 14)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revision surgery</measure>
    <time_frame>Day 0 - Day 14</time_frame>
    <description>Occurrence of revision surgery due to persistent discharge from the day of the operation (Day 0) until discharge from hospital (or max Day 14)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation</measure>
    <time_frame>Day 0 - Day 14</time_frame>
    <description>Duration of hospitalisation from Day 0 to end of hospitalisation (in days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>Day 7</time_frame>
    <description>Reported patient satisfaction based on the responses obtained from the &quot;Patient Evaluation Form&quot; questionnaire completed by the patient. A numeric pain scale is included: the patient rates his pain on a scale of 0 to 10 when the last dry dressing (Opsite TM) is changed or when Prevena system (TM) is removed. Zero means &quot;no pain,&quot; and 10 means &quot;the worst possible pain.&quot;Participant will complete the questionnaire on Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>Day 0 - Day 7</time_frame>
    <description>Dressing repair costs (sum of the price of all dressings and materials needed for dressing repair) from Day 0 to Day 7 (in Swiss francs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE &amp; ADE</measure>
    <time_frame>Day 0 - Day 14</time_frame>
    <description>Occurrence, intensity, severity, causal link with the medical device and the procedure, and characteristics of the adverse events (AEs) considered to be at least possibly related to the medical device or the procedure (= adverse events, ADEs), occurring from the day of the operation (Day 0) until discharge from hospital (or max Day 14).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Arthroplasty Complications</condition>
  <condition>Amputation</condition>
  <condition>Prosthesis-Related Infections</condition>
  <arm_group>
    <arm_group_label>Standard dry dressing in total hip or knee arthroplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard dressing in total hip or knee arthroplasty surgery revision: a dry sterile dressing is applied on the surgical wound at the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevena in total hip or knee arthroplasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prevena incision management system in total hip or knee arthroplastsy surgery revision:&#xD;
The Prevena incision management system is applied on the surgical wound at the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dry dressing in lower limb amputation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard dressing in lower limb amputation: a dry sterile dressing is applied on the surgical wound at the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevena in lower limb amputation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prevena incision management system in lower limb amputation:&#xD;
The Prevena incision management system is applied on the surgical wound at the end of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prevena TM</intervention_name>
    <description>A Prevena Plus DuoTM Dressing Kit (KCI) is applied on the surgical wound at the end of surgery.</description>
    <arm_group_label>Prevena in lower limb amputation</arm_group_label>
    <arm_group_label>Prevena in total hip or knee arthroplasty</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dry dressing</intervention_name>
    <description>A standard dry sterile dressingwith non-adherent absorbent pad is applied on the surgical wound at the end of surgery</description>
    <arm_group_label>Standard dry dressing in lower limb amputation</arm_group_label>
    <arm_group_label>Standard dry dressing in total hip or knee arthroplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Planned Surgery :&#xD;
&#xD;
               1. revision of a hip or knee prosthesis, in 1 or 2 stages, at explantation and/or&#xD;
                  reimplantation, where&#xD;
&#xD;
               2. elective amputation of a lower limb (transmetatarsal, trans-tibial (Burgess) or&#xD;
                  trans-femoral (Gritti-Stokes) level (nb: patients for whom amputation of both&#xD;
                  lower limbs is planned will be excluded)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to dry dressings&#xD;
&#xD;
          -  Patient already included in another clinical trial&#xD;
&#xD;
          -  Inability to discern and/or inability to follow study procedures&#xD;
&#xD;
          -  Known allergy to silver or another component of the system Prevena™&#xD;
&#xD;
          -  Amputation for tumor pathology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvain Steinmetz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lausanne University Hospital (Switzerland)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvain Steinmetz, MD</last_name>
    <phone>+41 (0)21 314 27 89</phone>
    <email>sylvain.steinmetz@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diane Wernly, MD</last_name>
    <phone>+41 (0)76 581 49 73</phone>
    <email>wernly.diane@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lausanne University Hospital</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Steinmetz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Diane Wernly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Borens, PR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne Hospitals</investigator_affiliation>
    <investigator_full_name>Sylvain Steinmetz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Prevena</keyword>
  <keyword>Negative Pressure Wound Therapy</keyword>
  <keyword>Revision Arthroplasty</keyword>
  <keyword>Lower Extremity Amputation Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prosthesis-Related Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

